At Otonomy, our mission is to develop and commercialize novel and best-in-class therapeutics to address the significant unmet medical needs in the emerging otology market. To overcome many of the limitations of delivering drugs to the ear, we have developed a proprietary technology that is designed to deliver drug that is retained in the ear for an extended period of time following a single local administration, which we refer to as ñsustained-exposure.î Utilizing this technology, we have advanced three product candidates into development for the respective treatment of middle ear effusion in pediatric patients undergoing tympanostomy tube placement (TTP) surgery, MeniereÍs disease and tinnitus. For more information about our company, our technology and our product candidates, visit www.otonomy.com.